OPIP Procurement Readiness: What Pharmacy Buying Groups Need to Lock In Before Summer 2026
The £85M NHS / Eli Lilly Obesity Pathway Innovation Programme runs its first pilots this summer. Buying-group procurement decisions are happening now. Here's what an OPIP-ready wraparound proposition has to demonstrate — and where most current bids fall short.
Key takeaways
- The NHS / Eli Lilly Obesity Pathway Innovation Programme (OPIP) launches its first community-pharmacy-led pilots in summer 2026. ICB-level commissioning decisions for the wider rollout follow through 2026–27.
- Pharmacy buying groups — Numark (6,000+ members), Alphega (1,000+), Avicenna (1,250+), Cohens, Day Lewis — are the procurement layer. A single buying-group decision deploys a wraparound platform across thousands of stores.
- OPIP-ready procurement has seven non-negotiable requirements: NICE-aligned BSOP content, SNOMED-CT coded outcome data, validated PROMs, clinician-linked escalation, MHRA-classified tooling, an NHS-interoperability roadmap, and a commissioner-grade audit dashboard.
- Most current bids fail on two of those seven: SNOMED coding and post-treatment relapse-prevention content. Both are visible to commissioners on first inspection of the data.
- The window to influence buying-group decisions closes through Q2–Q3 2026. Pharmacies that arrive at the OPIP pilot stage with integrated wraparound win the workflow; those that arrive reactive get whatever the group selected for them.
The Obesity Pathway Innovation Programme is the most consequential procurement event the UK weight-management market has produced. The £85M joint commitment from NHS England and Eli Lilly is not a small pilot — it is the operational template for how the NHS will deliver tirzepatide outside the Tier 3/4 specialist services that cannot scale to the 220,000-patient first-wave population.
By the time the pilots are running this summer, the procurement decisions that determine which platform is deployed in which thousand-store buying group will already have been made. For pharmacy operators, digital partners, and clinical content providers, the consequential window is now.
This article sets out what OPIP-ready procurement actually looks like, where current proposals are falling short, and the practical 90-day path to a credible bid.
What OPIP is, and what it isn’t
OPIP is the operationalisation of the wraparound requirement that NICE TA1026 attached to NHS-funded tirzepatide. The headline numbers — 220,000 patients in three years, 12-year phased rollout, primary-care access from June 2025 — describe the prescribing pathway. OPIP is the support structure around it.
Unlike a conventional NHS pilot, OPIP is structured as an evaluation programme rather than a procurement framework. ICBs and primary-care networks selected for the pilots will trial different delivery models — community-pharmacy-led with digital wraparound, primary-care-led with referral-out wraparound, and specialist-led for tertiary cases. The evaluation will compare outcomes, cost, and scalability across models. The community-pharmacy-led model is widely expected to come out as the dominant scalable option, on the simple grounds that it is the only channel with the geographic footprint and the clinical relationship to deliver at the volumes TA1026 implies.
What this means for procurement is that buying groups, pharmacy chains, and ICB commissioners are all making decisions now about the wraparound stack they will commit to — not in response to a single tender but in response to the structural inevitability of the OPIP-shaped market that follows.
Why procurement is happening upstream
For digital wraparound providers used to selling into individual pharmacies, OPIP changes the addressable customer. The deciders are not store managers and not ICBs in the first instance. They are the buying groups.
Numark sits at the top of this list with 6,000+ member pharmacies and a clinical services programme that has historically led pharmacy networks into NHS commissioning opportunities. Alphega Pharmacy operates a more curated network of 1,000+ members with a stronger emphasis on premium services. Avicenna Pharmacy supports 1,250+ independents with shared infrastructure. Cohens, Day Lewis and other regional groups round out the picture. Multiples — Boots, Lloyds, Well — make their own decisions but on the same timetable.
A buying-group decision in Q2 or Q3 2026 deploys a wraparound platform across the entire network for the OPIP pilots and, more importantly, for the post-pilot rollout that follows. The procurement decision is therefore made once and locks in the operational stack for years.
The buying groups are aware of this. Their procurement teams are running structured RFP processes through the spring. The clinical leads inside those buying groups are running parallel due-diligence on content fidelity. The decisions will get made well before any individual ICB tender goes live, because the buying group needs the stack ready when the tender lands.
The seven OPIP procurement requirements
Reading across NHS England’s interim TA1026 commissioning guidance, the OPIP programme materials, the NICE Early Value Assessment for digital weight-management providers, and the procurement requests already in the market from Numark and Alphega clinical teams, an OPIP-ready proposition needs to evidence seven things.
1. NICE-aligned BSOP content spine. All six BSOP components — appetite regulation, eating patterns, emotional regulation, movement progression, sleep and recovery, relapse prevention — covered with documented clinical review. Content reviewed against NICE NG246 (2025) and TA1026 evidence base. Pre-2025 content fails this test.
2. SNOMED-CT coded outcome data. Symptom logs, dose history, side-effect burden, treatment events captured against the NHS dictionary. Free-text symptom notes do not satisfy commissioners moving toward coded data for outcome comparison and population health analysis. The dm+d coding for tirzepatide and semaglutide preparations is the corresponding requirement on the medication side.
3. Validated patient-reported outcome measures. EQ-5D-5L for quality of life. A treatment-tolerability instrument such as TSQM. Side-effect burden capture mapped to MedDRA where possible. Weight is necessary but insufficient — commissioners increasingly read services that track only weight as not commissioning-grade.
4. Clinician-linked escalation pathway. Time-bound, auditable, with named clinical accountability and a documented escalation runbook. Digital-only delivery without a human escalation path will not pass clinical governance review at any serious buying group.
5. MHRA-classified digital tooling. Class I SaMD as a minimum, with active hazard log and DCB0129 / DCB0160 clinical safety case. The MHRA registration date matters: a registration completed in the last twelve months without a hazard log is not the same artefact as one with eighteen months of post-market surveillance. Buying groups now ask for both.
6. NHS interoperability position. NHS Login integration for patient identity. NHS Number capture and propagation. GP Connect plan or live integration for medication and observation propagation back to the patient record. Data residency in the UK. NHS Digital Data Security and Protection Toolkit (DSPT) compliance, current year.
7. Commissioner-grade audit dashboard. Engagement, outcomes, and safety data visualisable at the population level for ICBs and at the cohort level for the pharmacy operator. Dashboards that exist only for internal ops use are insufficient. ICB commissioners need to be able to log in, run a query, and pull a report that satisfies a tender review.
A proposition that evidences all seven is procurement-ready. A proposition that evidences six can compete but will be discounted at the clinical-review stage. A proposition that evidences five or fewer should not be in the OPIP conversation in 2026.
Where current bids fall short
Of the propositions currently being walked through buying-group RFP processes, the most common failure points are visible to anyone reviewing the data structure for an hour.
SNOMED gaps. Many platforms built between 2022 and 2024 captured symptoms in free-text or in a custom taxonomy. Retrofitting SNOMED-CT requires recoding historic data, mapping the existing taxonomy, and validating clinically. This is six to nine months of work and there is no shortcut. Vendors who claim “SNOMED-ready” without showing the dictionary file are flagged at clinical review.
Relapse-prevention content. BSOP coverage is often strong on the first five components and weak on the sixth. Content libraries written in 2023–24 reflected the assumption that GLP-1 treatment was indefinite. The post-discontinuation reality — food-noise return, the re-titration pathway if patients restart, the structural support for the off-treatment phase — is content most providers are still building. NICE TA875’s two-year cap on funded semaglutide makes this a commissioning-explicit requirement, not an optional extension.
No coded medication propagation. Wraparound platforms that capture dose changes locally without propagating them back as dm+d-coded medication events to the prescribing pharmacy or GP record are creating data silos. ICBs reviewing the OPIP evaluation will compare outcomes across propagated and non-propagated data; the latter looks worse on every metric because it isn’t visible.
Engagement-only outcome dashboards. A dashboard that shows “92% of patients opened their week-2 content” tells a buying group nothing about whether the service works. Outcome dashboards need to show weight trajectory by week, EQ-5D-5L change at three and six months, side-effect-driven discontinuation rates, and patient-reported satisfaction. Engagement metrics are a means, not an end.
Static MHRA registration. Class I SaMD registration is necessary but not differentiating. The hazard log, post-market surveillance documentation, and incident-reporting workflow are what serious clinical reviewers ask to see. Vendors with a registration certificate but no hazard log are common; vendors with both are not.
The buying-group decision dynamic
Buying-group procurement is a commercial decision with a clinical defensibility check. The procurement lead does not run the clinical review; the head of clinical services does. The two roles arrive at the decision through different filters and the proposition has to satisfy both.
The commercial filter looks at deployment cost per store, integration complexity with existing PMR systems, the commercial structure (per-patient, per-month, or revenue-share), liability and data-processing terms, and the implementation timeline. The clinical filter looks at NICE alignment, clinical content authorship, evidence of fidelity, escalation pathway, MHRA classification and post-market surveillance, and the population-level outcome story. The decision is made when both filters return green at the same time.
Vendors who optimise only for the commercial filter — slick demo, low integration cost, attractive commercials — fail at the clinical-defence stage when the head of services has to justify the decision to the buying group’s clinical governance committee. Vendors who optimise only for the clinical filter — best-in-class content, comprehensive evidence base — fail at the commercial-decision stage when the procurement lead can’t fit the integration into the operational plan. Both filters need to be met explicitly.
A 90-day readiness path
For a digital wraparound provider or a pharmacy clinical-services team that has read the seven requirements and recognised gaps, the practical timeline to readiness is approximately 90 days.
Days 1–30. Gap analysis and due-diligence pack. Run a structured comparison of current capability against each of the seven requirements. Score honestly. Commission an external clinical review of the BSOP content spine against NICE NG246 and TA1026. Begin assembly of the due-diligence pack: clinical authorship documentation, content review history, MHRA registration and hazard log, DSPT certification, and outcome data from current deployments.
Days 30–60. Code, capture, escalate. Lock the SNOMED-CT dictionary for symptom and event capture. Define the dm+d-coded medication-event schema and confirm propagation to the pharmacy or GP record. Build or review the PROM workflow — EQ-5D-5L at minimum, plus a tolerability measure. Document the clinician-linked escalation runbook and confirm named clinical accountability. Complete or update MHRA paperwork including hazard log entries from the past year.
Days 60–90. Pilot and dashboard. Deploy the updated stack in one or two pilot stores to capture two months of clean outcome data ahead of RFP responses. Build the commissioner-grade audit dashboard with engagement, outcomes, and safety views. Run a tabletop exercise simulating an ICB review of the dashboard: is the data legible at the population level? Does it support a tender response? Iterate.
A team that completes this 90-day path enters Q3 2026 with the evidence pack and the data needed to respond credibly to buying-group RFPs and the ICB tenders that follow.
The wider point
OPIP is the procurement event that fixes the operational template for NHS GLP-1 delivery for the next decade. The pilots in summer 2026 will run with whichever wraparound stack the buying groups have committed to in the preceding twelve months. Those commitments are being made now.
For pharmacy buying groups, the question is whether the wraparound stack you select can satisfy both the commercial and clinical filters at scale, can be deployed across thousands of stores without bespoke integration, and can produce the audit data ICBs will ask for in 2027–28 tender cycles. For digital providers, the question is whether your proposition has all seven requirements documented today — not whether you can build them when asked. By the time you can build them, the decision has been made.
The pharmacies that engage this procurement window with a complete proposition will be the ones running the OPIP-shaped market on the other side of the pilots. The ones that engage reactively will be running whatever their buying group selected without their input.
Cadence Health delivers OPIP-ready GLP-1 wraparound: NICE-aligned 52-week BSOP content covering all six components including post-discontinuation, SNOMED-CT and dm+d coded data flowing into a commissioner-grade dashboard, validated EQ-5D-5L and tolerability PROM workflow, clinician-linked escalation, and MHRA Class I SaMD registration with active hazard log. We work with pharmacy buying groups and operators on procurement-stage deployments. Get in touch at hello@cadencehealth.uk.
References: NICE TA1026 Tirzepatide for managing overweight and obesity (December 2024); NICE TA875 Semaglutide for managing overweight and obesity (September 2023); NICE NG246 Overweight and Obesity Management (2025); NHS England Interim Commissioning Guidance for Implementation of NICE TA1026 (March 2025); NHS England / Eli Lilly Obesity Pathway Innovation Programme materials (2025); NICE Early Value Assessment for Digital Weight Management Technologies (August 2023); NHS Digital Data Security and Protection Toolkit (DSPT) requirements; NHS Digital SNOMED-CT and dm+d implementation guidance; Numark, Alphega and Avicenna clinical services programme materials.